Boston Scientific Corp (BSX)vsGlaukos Corp (GKOS)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
GKOS
Glaukos Corp
$109.60
+4.15%
HEALTHCARE · Cap: $6.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 3856% more annual revenue ($20.07B vs $507.44M). BSX leads profitability with a 14.4% profit margin vs -37.0%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
GKOS
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Intrinsic value data unavailable for GKOS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Revenue surging 35.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 9.6x book value
Weak financial health signals
ROE of -26.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : GKOS
The strongest argument for GKOS centers on Revenue Growth. Revenue growth of 35.7% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : GKOS
The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a growth stock while GKOS is a hypergrowth play — different risk/reward profiles.
GKOS carries more volatility with a beta of 0.74 — expect wider price swings.
GKOS is growing revenue faster at 35.7% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 44/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Glaukos Corp
HEALTHCARE · MEDICAL DEVICES · USA
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?